Bavarian Nordic announces expansion of Imvamune orders from Canadian government
![](/46/pdcnewsitem/04/13/05/bavarian%20nordic.jpg)
PHAC orders a total of 360,000 doses of the smallpox vaccine.
Bavarian Nordic has announced that the Public Health Agency of Canada (PHAC) has exercised an option for the supply of 171,000 doses of Imvamune smallpox vaccine to the national stockpile at a total value of $7.7 million.
This option builds upon an initial order of 189,000 doses, comprising a total of 360,000 doses ordered by PHAC, to date. Deliveries from the initial order are taking place throughout 2016, and the new order will be delivered in 2017 and 2018. The company also has an ongoing contract with the Canadian Department of National Defence (DND), under which additional options for Imvamune remain exercisable. Approved in Canada in 2013, Imvamune is a non-replicating smallpox vaccine, which is being stockpiled for use in both the general population as well as individuals who are contraindicated to traditional smallpox vaccines, such as HIV-infected and people suffering from skin disorders.
Paul Chaplin, President & CEO of Bavarian Nordic, said: "We are pleased to continue our collaboration with the Canadian government in their efforts to secure protection for its citizens. This collaboration dates back to 2008 when we started deliveries to the Canadian Department of National Defence, and was since broadened to include the Public Health Agency of Canada, who also recognized the need for establishing a smallpox vaccine stockpile for the general population. We look forward to continuing and expanding our partnership engagement on various bio preparedness matters, including smallpox."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance